Multiple pharmaceutical companies actively layout chronic disease Market

Many pharmaceutical companies, such as Yuheng Pharmaceutical Co., Ltd and China Resources Shuanghe Pharmaceutical Co., Ltd., have been actively engaged in the field of chronic diseases, even purchasing relevant enterprises at a high premium At the same time, according to relevant reports, in 2016, China spent about 3.24 trillion yuan on chronic diseases Industry insiders said that although the chronic disease market is huge, domestic high-quality pharmaceutical assets are relatively scarce In order to successfully acquire related assets, listed companies may acquire them at a high premium Yuheng Pharmaceutical Co., Ltd announced that the company plans to acquire no less than 35% of the transferable and unencumbered equity of Hefei Tianmai Biotechnology Development Co., Ltd (hereinafter referred to as "Tianmai bio") and obtain the control right over the subject matter of the transaction It is expected that the consideration of the transaction will not be less than 4 billion yuan Yuheng pharmaceutical said to reporters that one of the company's current strategic directions is to focus on the chronic disease field, mainly looking for products that pass the consistency evaluation, and to code the chronic disease field by means of strategic cooperation, M & A and agency In addition, the company will also carry out strategic cooperation with foreign relevant excellent enterprises or introduce products with market potential in the field of chronic diseases The data shows that Tianmai biology is committed to the international cooperation, joint development, application for registration, production and sales of insulin and insulin analogues Up to now, it has obtained the production approval of recombinant human insulin injection, and has distributed multiple products such as recombinant human insulin injection of protamine It is worth mentioning that Tianmai bio has made a performance commitment to Yuheng pharmaceutical industry, that is, the total net profit of the audited transaction target in the three fiscal years 2018-2020 in the performance commitment period will reach 1.8 billion yuan With the increasing scarcity of domestic high-quality medical assets, overseas "drug seeking" has become the norm Tianshi also announced recently that it has recently signed a license agreement with Japan EA Pharmaceutical Co., Ltd (hereinafter referred to as "EA pharmaceutical") to introduce a calcium sensing receptor modifier (hereinafter referred to as "ajt240") for the treatment of patients with secondary hyperparathyroidism (SHPT) caused by late renal function damage and hemodialysis Data show that SHPT is one of the common and serious complications in patients with chronic kidney disease (CKD), which is an important pathological basis for cardiovascular complications in CKD Ajt240 has a sustained and stable PTH lowering effect The huge market attracts enterprises to compete in the field of chronic diseases The blue book of health management: report on the development of China's health management and health industry (2018) points out that at present, the number of chronic diseases in China is about 300 million, and the burden of chronic diseases for people under 65 years old accounts for 50% Because of the characteristics of chronic diseases, such as large number of patients, long medication time, high cost of drugs, strong dependence on medical treatment, and large demand for treatment and maintenance According to China's medium and long term plan for the prevention and control of chronic diseases (2017-2025), in 2016, China spent about 3.24 trillion yuan on chronic diseases High premium acquisition will become the norm, said Shi lichen, founder of McConnell Although the chronic disease market is huge, domestic high-quality medical assets are scarce In order to successfully acquire related assets, listed companies will purchase medical assets at a high premium Taking China Resources Shuanghe as an example, it recently said that it plans to purchase 40% equity of China Resources Shuanghe Limin Pharmaceutical (Jinan) Co., Ltd (hereinafter referred to as "Shuanghe Limin") for 848 million yuan Upon completion of the acquisition, China Resources Shuanghe will hold 100% of the equity of Shuanghe Limin The purchase price is 316.20% higher than the book value The data showed that shuanghelimin mainly had citicoline sodium tablets for the treatment of neurological sequelae, irbesartan dispersible tablets for the treatment of hypertension and nifedipine sustained-release tablets (Ⅱ) for the treatment of angina pectoris and essential hypertension In 2017, the company achieved revenue of 722 million yuan and net profit of 118 million yuan; in the first quarter of this year, the company achieved revenue of 284 million yuan and net profit of 37 million yuan However, there are also the target assets acquired by enterprises in a loss state Recently, xinlitai announced that the company plans to transfer 100% equity of Jiangsu Huanchen Medical Technology Co., Ltd (hereinafter referred to as "Huanchen medical") for 473 million yuan Huanchen medical is mainly engaged in the research, development, production and sales of cardiac interventional medical devices Its main product is drug-eluting coronary stent system, which is mainly used to improve the symptoms of vascular stenosis in patients with ischemic heart disease, including myocardial ischemia or angina caused by coronary stenosis or occlusion In terms of performance, Huanchen medical lost 13.6911 million yuan in net profit in 2017 and 1.7348 million yuan in net profit in the first quarter of this year.